^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

Excerpt:
...Quantitative change in the sum of Response Evaluation Criteria in Solid Tumors (RECIST) - measurable index lesions on paired, pre-and post-treatment computed tomography scans (delta change in T)`Will compare quantitative change in tumor size (change in T) in patients with genomic PIK3CA pathway alteration (PIK3CA mutation, amplification, and fluorescence in situ hybridization [FISH] for PTEN loss) versus no genomic activation.`...
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer

Excerpt:
The PIK3CA-mutant cell lines were more sensitive to BYL719 than the PIK3CA wild-type cell lines.